Bhupesh Panwar1, Nancy S Jenny1, Virginia J Howard1, Virginia G Wadley1, Paul Muntner1, Brett M Kissela1, Suzanne E Judd1, Orlando M Gutiérrez2. 1. From the Departments of Medicine (B.P., V.G.W., P.M., O.M.G.), Epidemiology (V.J.H., P.M., O.M.G.), and Biostatistics (S.E.J.), University of Alabama at Birmingham; Department of Pathology, University of Vermont, Burlington (N.S.J.); and Department of Neurology, University of Cincinnati, OH (B.M.K.). 2. From the Departments of Medicine (B.P., V.G.W., P.M., O.M.G.), Epidemiology (V.J.H., P.M., O.M.G.), and Biostatistics (S.E.J.), University of Alabama at Birmingham; Department of Pathology, University of Vermont, Burlington (N.S.J.); and Department of Neurology, University of Cincinnati, OH (B.M.K.). ogutierr@uab.edu.
Abstract
BACKGROUND AND PURPOSE:Fibroblast growth factor 23 (FGF23) is a hormone that regulates phosphorus and vitamin D metabolism. Elevated FGF23 concentrations are associated with excess risk of cardiovascular disease. Associations of FGF23 with stroke outcomes are less clear. METHODS: Using a case-cohort study design, we examined the association of baseline plasma FGF23 concentrations with incident stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a cohort of black and white adults aged ≥45 years. FGF23 was measured in 615 participants who developed incident stroke (cases) and in 936 participants randomly selected from the REGARDS cohort (comparison subcohort). RESULTS: In multivariable-adjusted models, higher calcium and phosphorus concentrations, lower estimated glomerular filtration rate and higher urine albumin excretion were independently associated with higher FGF23. There was no statistically significant association of FGF23 with risk of all-cause stroke in Cox models adjusted for demographic factors and established stroke risk factors (hazard ratio comparing fourth with first quartile 1.19; 95% confidence interval, 0.78-1.82). In prespecified models stratified by stroke subtypes, there was a graded association of FGF23 with risk of cardioembolic stroke in fully adjusted models (quartile 1, reference; quartile 2 hazard ratio, 1.48; 95% confidence interval, 0.63-3.47; quartile 3 hazard ratio, 1.99; 95% confidence interval, 0.89-4.44; quartile 4 hazard ratio, 2.52; 95% confidence interval, 1.08-5.91). There were no statistically significant associations of FGF23 with other ischemic stroke subtypes or with hemorrhagic strokes. CONCLUSIONS: Higher FGF23 concentrations were associated with higher risk of cardioembolic but not with other stroke subtypes in community-dwelling adults. Additional studies should delineate reasons for these findings.
RCT Entities:
BACKGROUND AND PURPOSE:Fibroblast growth factor 23 (FGF23) is a hormone that regulates phosphorus and vitamin D metabolism. Elevated FGF23 concentrations are associated with excess risk of cardiovascular disease. Associations of FGF23 with stroke outcomes are less clear. METHODS: Using a case-cohort study design, we examined the association of baseline plasma FGF23 concentrations with incident stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a cohort of black and white adults aged ≥45 years. FGF23 was measured in 615 participants who developed incident stroke (cases) and in 936 participants randomly selected from the REGARDS cohort (comparison subcohort). RESULTS: In multivariable-adjusted models, higher calcium and phosphorus concentrations, lower estimated glomerular filtration rate and higher urine albumin excretion were independently associated with higher FGF23. There was no statistically significant association of FGF23 with risk of all-cause stroke in Cox models adjusted for demographic factors and established stroke risk factors (hazard ratio comparing fourth with first quartile 1.19; 95% confidence interval, 0.78-1.82). In prespecified models stratified by stroke subtypes, there was a graded association of FGF23 with risk of cardioembolic stroke in fully adjusted models (quartile 1, reference; quartile 2 hazard ratio, 1.48; 95% confidence interval, 0.63-3.47; quartile 3 hazard ratio, 1.99; 95% confidence interval, 0.89-4.44; quartile 4 hazard ratio, 2.52; 95% confidence interval, 1.08-5.91). There were no statistically significant associations of FGF23 with other ischemic stroke subtypes or with hemorrhagic strokes. CONCLUSIONS: Higher FGF23 concentrations were associated with higher risk of cardioembolic but not with other stroke subtypes in community-dwelling adults. Additional studies should delineate reasons for these findings.
Authors: Anna Jovanovich; Joachim H Ix; John Gottdiener; Kim McFann; Ronit Katz; Bryan Kestenbaum; Ian H de Boer; Mark Sarnak; Michael G Shlipak; Kenneth J Mukamal; David Siscovick; Michel Chonchol Journal: Atherosclerosis Date: 2013-09-13 Impact factor: 5.162
Authors: Mary Cushman; Suzanne E Judd; Virginia J Howard; Brett Kissela; Orlando M Gutiérrez; Nancy S Jenny; Ali Ahmed; Evan L Thacker; Neil A Zakai Journal: Stroke Date: 2014-04-22 Impact factor: 7.914
Authors: Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard Journal: Neuroepidemiology Date: 2005-06-29 Impact factor: 3.282
Authors: Jessica Kendrick; Alfred K Cheung; James S Kaufman; Tom Greene; William L Roberts; Gerard Smits; Michel Chonchol Journal: J Am Soc Nephrol Date: 2011-09-07 Impact factor: 10.121
Authors: Chad D Touchberry; Troy M Green; Vladimir Tchikrizov; Jaimee E Mannix; Tiffany F Mao; Brandon W Carney; Magdy Girgis; Robert J Vincent; Lori A Wetmore; Buddhadeb Dawn; Lynda F Bonewald; Jason R Stubbs; Michael J Wacker Journal: Am J Physiol Endocrinol Metab Date: 2013-02-26 Impact factor: 4.310
Authors: Latha Ganti Stead; Rachel M Gilmore; M Fernanda Bellolio; Anunaya Jain; Alejandro A Rabinstein; Wyatt W Decker; Dipti Agarwal; Robert D Brown Journal: Stroke Res Treat Date: 2011-10-10
Authors: P G Wiklund; W M Brown; T G Brott; B Stegmayr; R D Brown; S Nilsson-Ardnor; J A Hardy; B M Kissela; A Singleton; D Holmberg; S S Rich; J F Meschia Journal: Neurology Date: 2007-02-06 Impact factor: 9.910
Authors: Nirav H Shah; Chuanhui Dong; Mitchell S V Elkind; Ralph L Sacco; Armando J Mendez; Barry I Hudson; Shonni Silverberg; Myles Wolf; Tatjana Rundek; Clinton B Wright Journal: Arterioscler Thromb Vasc Biol Date: 2015-06-25 Impact factor: 8.311
Authors: Clinton B Wright; Nirav H Shah; Armando J Mendez; Janet T DeRosa; Mitsuhiro Yoshita; Mitchell S V Elkind; Ralph L Sacco; Charles DeCarli; Tatjana Rundek; Shonni Silverberg; Chuanhui Dong; Myles Wolf Journal: Stroke Date: 2016-03-08 Impact factor: 7.914
Authors: Amarnath Marthi; Killian Donovan; Richard Haynes; David C Wheeler; Colin Baigent; Christopher M Rooney; Martin J Landray; Sharon M Moe; Jun Yang; Lisa Holland; Romina di Giuseppe; Annet Bouma-de Krijger; Borislava Mihaylova; William G Herrington Journal: J Am Soc Nephrol Date: 2018-05-15 Impact factor: 10.121
Authors: Fred Stephen Sarfo; Rufus Akinyemi; George Howard; Virginia J Howard; Kolawole Wahab; Mary Cushman; Deborah A Levine; Adesola Ogunniyi; Fred Unverzagt; Mayowa Owolabi; Bruce Ovbiagele Journal: J Neurol Sci Date: 2020-02-19 Impact factor: 4.553
Authors: Ninad S Chaudhary; S Louis Bridges; Kenneth G Saag; Elizabeth J Rahn; Jeffrey R Curtis; Angelo Gaffo; Nita A Limdi; Emily B Levitan; Jasvinder A Singh; Lisandro D Colantonio; George Howard; Mary Cushman; Matthew L Flaherty; Suzanne Judd; Marguerite R Irvin; Richard J Reynolds Journal: Hypertension Date: 2019-12-02 Impact factor: 10.190
Authors: J X Moore; N A Zakai; M Mahalingam; R L Griffin; M R Irvin; M M Safford; J W Baddley; H E Wang Journal: J Thromb Haemost Date: 2016-09-23 Impact factor: 5.824